Editorial: A tissue selective estrogen complex: A new horizon for menopausal symptoms

Menopause

Volumn 16, Issue 6, 2009, Pages 1083-1084

  Warren, Michelle P ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HERBACEOUS AGENT; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BLEEDING; BLOATING; BREAST CANCER; CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MONOTHERAPY; MOOD DISORDER; PATIENT COMPLIANCE; QUALITY OF LIFE; SLEEP DISORDER; STROKE; UNSPECIFIED SIDE EFFECT; VASOMOTOR DISORDER; MENOPAUSE; MIDDLE AGED; NOTE; PHYSIOLOGY;

ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; MIDDLE AGED; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 73249121418     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181baa9cc     Document Type: Editorial

References (11)

1. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
2. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071. (Pubitemid 44794007)
3. Pinkerton JV, Utian WU, Constatine GD, Oliver SO, Pickar JH, Relief of vasomotor symptoms with the tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens: a randomized controlled trial. Menopause 2009;16:1116-1124.
4. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-1024.
5. Lobo RA, Pinkerton JV, Gass MLS, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
6. Pinkerton JV, Utian WH, Archer DF, Levine A, Chines AA, Constantine G. Endometrial and ovarian safety of bazedoxifene (BZA) in the prevention of postmenopausal osteoporosis. Fertil Steril 2007; 88:S241-S242.
7. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placeboand active-controlled clinical trial. J Bone Miner Res 2008;23:1923-1934.
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
9. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, JAMA 2004; 291:1701-1712. (Pubitemid 38489892)
10. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365. (Pubitemid 43244325)
11. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-2434. (Pubitemid 43948050)